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microRNA-21 (miR-21) is the most commonly upregulated miRNA in solid tumors. This cancer-associated microRNA
(oncomiR) regulates various downstream effectors associated with tumor pathogenesis during all stages of carcinogenesis.
In this study, we analyzed the function of miR-21 in noncancer cells of the tumor microenvironment to further evaluate its
contribution to tumor progression. We report that the expression of miR-21 in cells of the tumor immune infiltrate, and in
particular in macrophages, was responsible for promoting tumor growth. Absence of miR-21 expression in tumor- associated
macrophages (TAMs), caused a global rewiring of their transcriptional regulatory network that was skewed toward a
proinflammatory angiostatic phenotype. This promoted an antitumoral immune response characterized by a macrophagemediated improvement of cytotoxic T-cell responses through the induction of cytokines and chemokines, including IL-12 and
C-X-C motif chemokine 10. These effects translated to a reduction in tumor neovascularization and an induction of tumor
cell death that led to decreased tumor growth. Additionally, using the carrier peptide pH (low) insertion peptide, we were
able to target miR-21 in TAMs, which decreased tumor growth even under conditions where miR-21 expression was deficient
in cancer cells. Consequently, miR-21 inhibition in TAMs induced an angiostatic and immunostimulatory activation with
potential therapeutic implications.

Introduction

miRNAs are small endogenous non–protein-coding RNAs that
posttranscriptionally regulate the expression of multiple target
genes in different cell types. In this manner, miRNAs control many
physiological cellular processes, as well as several pathologies.
Widespread dysregulation of miRNA expression has been reported in tumor cells, with either an oncogenic or a tumor suppressive
role (1). Given their pivotal role in tumor initiation, progression,
and response to therapy, these molecules have been accepted as
potential cancer biomarkers (2). During neoplastic development,
miRNAs have also been reported to be dysregulated in cells from
the tumor microenvironment (TME) (3). Therefore, their role in
cancer progression is not just limited to regulating cancer cell
behavior. The nonmalignant cells of the TME have a dynamic

Conflict of interest: DLR is a cofounder of, consultant for, and stockholder in HistoRx,
the exclusive license of the Yale-owned AQUA technology. YKR is a founder of pHLIP
Inc., with shares in the company.
Copyright: © 2019 Sharaei et al. This is an open access article published under the
terms of the Creative Commons Attribution 4.0 International License.
Submitted: January 2, 2019; Accepted: September 10, 2019; Published: November 11, 2019.
Reference information: J Clin Invest. 2019;129(12):5518–5536.
https://doi.org/10.1172/JCI127125.

5518

jci.org   Volume 129   Number 12   December 2019

and often tumor-supporting function (4), thus contributing to
the clinicopathological profile and to the efficacy of anticancer
therapy. The TME contains diverse types of cells, including cells
of the immune system, endothelial cells, and fibroblasts. Recent
studies have begun to unravel the cell-autonomous significance of
miRNAs in macrophages, T cells, and endothelial cells (ECs) and
their potential implications for cancer (5–7).
miR-21 is the most commonly upregulated miRNA in solid
tumors and hematological malignancies, and many studies have
linked this cancer-associated microRNA (oncomiR) to poor prognosis and survival (8). The contribution of miR-21 to tumorigenesis has been extensively studied in the context of cancer cells, as
it regulates various downstream effectors associated with tumor
pathogenesis including cell invasion, proliferation, migration,
apoptosis, and chemoresistance (8, 9). The role of miR-21 in cells
of the TME, however, has not been comprehensively studied. miR21 is the most abundant miRNA in macrophages (10) and highly
expressed in ECs and T lymphocytes (11, 12). Several reports have
described the role of miR-21 in regulating cellular functions that
may have an impact on tumor growth, such as the inflammatory responses of macrophages, T-cell activation and endothelial
angiogenic functions (12–18). However, the conclusions of these
reports are inconsistent and in most cases are not directly studied
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Figure 1. miR-21–deficient mice develop smaller tumors.
(A–D) Tumor analysis of WT and miR-21–/– mice with s.c.
injection of LLCs in the dorsal flank (n = 5). Tumor volume (A),
final tumor weight (B). (C) Representative images of TUNEL
and DAPI staining of cross sections of LLC tumors. Right panel:
Quantification of %DAPI+ TUNEL+ cells. (D) Representative
images of CD31 and DAPI immunostaining. Right panel: Quantification of CD31+ vessel-like structures. Results are mean ±
SEM. *P < 0.05. (A) Two-way ANOVA (time and genotype) with
Bonferroni correction, #P < 0.05 individual comparisons. (B–D)
Mann-Whitney U test. (A–D) Representative experiments out
of 3 with similar results. Scale bars: 70 μm.

in the context of tumor progression. In other instances, the studies relied on culture systems to inhibit or overexpress miR-21, or
approaches to globally target miR-21 in a non–cell/tissue-specific
manner (19–23). Recent attempts to understand the role of miR21 within immune infiltrating cells have also yielded conflicting
results mostly due to lack of experimental data on cell-type specific KO or cell-type specific targeting approaches (24, 25).
In this work, we have analyzed the function of miR-21 in noncancerous cells of the TME to determine its contribution to tumor
progression. To this end, we used a syngeneic tumor mouse model
and comprehensively assessed the effect of miR-21 deficiency in
different cells/tissues on tumor progression. Briefly, our results
indicate that the expression of miR-21 in macrophages of the tumor
immune infiltrate plays a pivotal role in the regulation of tumor
progression. Specifically, we found that both deletion and targeted
inhibition of miR-21 in tumor-associated macrophages promotes
proinflammatory angiostatic functions. This results in reduced
tumor neovascularization and an antitumoral immune response,
which is characterized by a macrophage-mediated improvement
of cytotoxic T-cell responses. Together, these effects led to diminished tumor growth.

Results

miR-21–deficient mice develop smaller tumors. In this study, we
aimed to analyze the role of miR-21 in noncancerous cells of the
TME on regulation of tumor progression. We used the Lewis lung
carcinoma (LLC) model, which is a syngeneic, hence immunologically compatible model, and analyzed tumor growth in both WT
and miR-21 KO mice (miR-21–/–). As shown in Figure 1, A and B,
miR-21–/– mice developed tumors with reduced volume and weight
when compared with WT controls. Tumors of miR-21–/– mice

exhibited an increased number of TUNEL-positive cells (Figure
1C) and reduced tumor-associated vasculature, as shown by the
diminished CD31+ vessel-like structures (Figure 1D). These results
indicate that loss of miR-21 increases tumor cell death, diminishes
tumor angiogenesis, and provides evidence that miR-21 expression in cells other than cancer cells has an important role in promoting tumor growth.
Lack of miR-21 expression in immune cells is responsible for
reduced tumor burden. To eliminate the role of stromal cells (e.g.,
fibroblasts, ECs) in limiting tumor growth of miR-21–/– mice, WT
mice were lethally irradiated and subsequently transplanted with
WT or miR-21–/– BM. Mice transplanted with miR-21–/– BM developed smaller tumors (Figure 2, A and B). Histological analysis of
their tumors revealed both increased TUNEL-positive cells and
decreased vascularization (Figure 2, C and D). Interestingly, a
reverse transplant of WT or miR-21–/– BM into miR-21–/– mice resulted in larger tumors in mice transplanted with WT BM (Figure 2, E
and F), with decreased TUNEL-positive cells and increased CD31+
vessel- like structures (Figure 2, G and H). These results suggest
that miR-21 expression within the tumor immune infiltrate is
responsible for promoting tumor growth and that its deletion causes increased tumor cell death and decreased tumor angiogenesis.
Tumor immune infiltrate of miR-21–/– or WT mice adoptively
transferred with miR-21–/– BM is characterized by the presence of
tumor-associated macrophages with an enhanced differentiated phenotype. Then, we examined the tumor-infiltrating immune cells
in LLC tumors of either WT or miR-21–/– mice as well as WT mice
adoptively transferred with WT or miR-21–/– BM. We analyzed the
frequency of immune cells related to tumor development, including myeloid-derived suppressor cells (MDSCs), tumor-infiltrating
lymphocytes (TILs), and macrophages (4). We did not find differjci.org   Volume 129   Number 12   December 2019
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Figure 2. Hematopoietic miR-21 regulates and promotes
tumor progression. (A–D) Tumor analysis of WT mice
transplanted with WT or miR-21–/– BM and injected with LLCs
s.c. (n = 7). LLC tumor volume (A), final tumor weight (B). (C)
Representative images of TUNEL and DAPI staining of cross
sections of LLC tumors. Right panel: Quantification of %DAPI+
TUNEL+ cells (n = 5 out of 7 randomly selected). (D) Representative images of CD31 and DAPI immunostaining. Right panel:
Quantification of CD31+ vessel-like structures (n = 6 out of 7
randomly selected). (E–H) Tumor analysis of miR-21–/– mice
transplanted with WT or miR-21–/– BM cells and injected with
LLCs s.c. (n = 5). Tumor volume (E), final tumor weight (F). (G)
Representative images of TUNEL and DAPI staining of cross
sections of LLC tumors. Right panel: Quantification of %DAPI+
TUNEL+ cells. (H) Representative images of CD31 and DAPI
immunostaining. Right panel: Quantification of CD31+ vessellike structures (n = 4 out of 5 randomly selected). Results are
mean ± SEM. *P < 0.05. (A and E) Two-way ANOVA (time and
genotype) with Bonferroni correction, #P < 0.05 individual
comparisons. (B–D and F–H) Mann-Whitney U test. (A–H)
Representative experiments out of 2 with similar results.
Scale bars: 70 μm.

ences in the percentage of MDSCs in the tumors of miR-21–/– mice
or the proportion of monocytic or granulocytic MDSCs (Supplemental Figure 1A; supplemental material available online with
this article; https://doi.org/10.1172/JCI127125DS1). We also did
not detect differences in the percentage of CD4+ or CD8+ T cells in
tumors from miR-21–/– mice or tumors from WT mice with miR-21–/–
5520
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BM (Supplemental Figure 1, B and C). Furthermore, the
proportion of IFNG expressing CD4+ or CD8+ T cells
was similar in tumors from WT and miR-21–/– mice (Supplemental Figure 1D), suggesting that the percentage of
activated T cells was equivalent.
We did, however, find a significant reduction in
TAM infiltration in miR-21–/– mice and mice transferred
with miR-21–/– BM (Figure 3, A and B) and a decreased
percentage of TAMs expressing C-C chemokine receptor type 2, although the level of surface expression was
not affected (Supplemental Figure 1E). In both miR-21–/–
animals and mice transferred with miR-21–/– BM, we
found that infiltrated TAMs exhibited increased surface
expression of MHC class II (MHC II) (Figure 3, C and
D). MHC II+high TAMs are better fosters of antitumor
immune responses (26). Altogether, these data show
that macrophages lacking miR-21 have reduced infiltration into the TME, and those present have a phenotype
more associated with tumor growth suppression.
Expression of miR-21 in TAMs regulates disease outcome. miR-21 is the most consistently overexpressed
miRNA across tumor types (8) and is associated with
poor prognosis (27). In solid tumors, these analyses
were based on total tumor RNA, which lacks critical
spatial information. We used quantitative ISH (qISH) to
directly assess the colocalization of miRNA expression
with tumor epithelial and/or other subcellular compartments by multiplexing with DAPI and cytokeratin
immunofluorescence (28, 29). To determine the prognostic value of miR-21 expression in the major tumor
compartments tumor islets [TIs] vs. TME), we used 3
retrospective non–small cell lung carcinoma (NSCLC) cohorts from
Yale University (Supplemental Tables 1–3). NSCLC represents the
most common subtype of lung cancer (30). These tissue microarrays (TMA) termed YTMA 79, 14, or 250, are composed of surgical resection samples from 290 patients with NSCLC. In order to
validate miR-21 qISH, we first assessed miR-21 qISH on heart and
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Figure 3. TAMs of miR-21–/– or WT mice adoptively transferred with miR-21–/– BM have an enhanced differentiated phenotype. (A) Left panel: Representative flow cytometry plots of TAM detection in s.c. LLC tumors of WT and miR-21–/– mice. TAMs were gated as CD45+ CD11b+ MHC II+ F4/80+ cells of the
digested tumor. Right panel: Average % TAMs (n = 4 out of 5 randomly selected). (B) Average % TAMs of LLC tumors in WT mice transplanted with WT or
miR-21–/– BM cells (n = 6 out of 7 randomly selected). (C and D) Representative histograms of MHC II surface expression in TAMs of s.c. LLC tumors of WT
or miR-21–/– (C), or WT mice transplanted with WT or miR-21–/– BM cells (D) a.u.f., arbitrary units of fluorescence. Right panels: Average MFI (n = 4 out of 5
randomly selected for C or n = 6 out of 7 randomly selected for D). Results are mean ± SEM. (A–D) *P < 0.05, Mann-Whitney U test. (A and D) Representative experiments out of 3 with similar results. (B and D) Representative experiments out of 2 with similar results.

spleen tissue from an miR-21–/– mouse (28). No specific signal for
miR-21 could be detected in heart and spleen compared with normal WT (Supplemental Figure 2A). On the TMA, we found that the
expression of miR-21 in tumor epithelial cells within TI was not
associated with 5-year overall survival (OS) (Figure 4A). In nontumor cells of the TME (Figure 4B), however, there was significant
prognostic effect on 5-year OS with a worse survival for patients
with high levels of miR-21 expression if they were stratified by the
median. Combined analysis of the expression of miR-21 in TI and
the TME did not show a significant effect on OS (Figure 4C). This
finding indicates that high miR-21 expression in cells of the TME
(non-tumor cells) has a negative impact on OS.
We then analyzed the expression of miR-21 in both compartments and found that the level of miR-21 expression was slightly
higher in TI when compared with the TME (Figure 4D). Despite
this fact, high expression of miR-21 in the TME was associated with
a worse prognostic value (Figure 4B). This finding is in agreement
with data showing that miR-21 expression in noncancerous cells of
the tumor contributes to the pathogenesis of lung cancer (31).
miR-21 is highly expressed in the monocytic/macrophage lineage (32) and the most abundant miRNA in macrophages (10). In
order to determine the levels of miR-21 in immune cells of LLC
tumors, we challenged WT mice with eGFP-LLCs and after 14
days, TAMs (CD45+, CD11b+, MHC II+, F4/80+), LLCs (eGFP+) and
TILs (CD45+, F4/80–) were sorted and the miR-21 levels analyzed.
Within the tumor, we found that miR-21 was highly expressed in
TAMs compared with the rest of the immune infiltrate and tumor
cells (eGFP-LLCs) (Supplemental Figure 2B). Likewise, miR-21
levels were higher in BM-derived macrophages (BMDMs) compared with LLCs in culture (Supplemental Figure 2C).
A high density of TAMs was associated with worse survival in
gastric cancer and head and neck cancer but better OS in patients

with colorectal cancer (33). In patients with lung cancer, conflicting data have been reported (34, 35). We used CD68 immunofluorescence to detect macrophages in our TMAs and found CD68+
macrophages present in all tumor TMA spots of NSCLC cohorts (n
= 240) in both the TI and TME (Figure 4D). A total of 50.1% of all
miR-21–expressing cells were CD68+ (Figure 4F). Although TME
areas were slightly enriched in CD68+ miR-21+ cells (Figure 4G),
double positive cells could be found in both compartments (Figure
4E), and the level of miR-21 expression was similar (Figure 4E).
We thus analyzed the contribution of miR-21 expression in macrophages to patients’ survival. We found that the level of expression
of miR-21 in CD68+ cells present within TI was not associated with
5-year OS (Figure 4H). When the analysis was performed within
the TME (Figure 4I), however, there was significantly worse survival for patients with high levels of miR-21 in CD68+ cells when
they were stratified by the median. Combined analysis of the
expression of miR-21 in CD68+ cells of TI and the TME (Figure
4J) showed a slight reduction in patients’ survival when miR-21 is
high in tumor macrophages. Altogether, these data indicate that
although miR-21 expression in macrophages is heterogeneously
localized within the tumor, the level of expression of miR-21 in
macrophages and in particular, in macrophages within the TME
can predict patient survival.
miR-21–deficient TAMs express a gene signature associated with
the promotion of a robust antitumor immune function. To elucidate
the role of miR-21 in regulating TAM function, we isolated TAMs
from LLC tumors of either miR-21–/– or WT mice and profiled their
transcriptomes by RNA-Seq. miR-21–/– TAM gene expression patterns were distinct from WT TAMs (Supplemental Figure 3A).
Hierarchical clustering of log ratio transformed gene expression
values of 1,035 genes that were differentially and significantly
expressed (FC > 1.5, P ≤ 0.005 B-H FDR) showed the level of tranjci.org   Volume 129   Number 12   December 2019
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Figure 4. High expression of miR-21 in CD68+ cells of the TME of NSCLC regulates disease outcome. (A–C) Kaplan-Meier 5-year OS survival curves of
patients with NSCLC in a combined analysis of 3 Yale cohorts; patients were stratified by the median of normalized miR-21–positive cell counts in (A) TIs,
(B) TME, and (C) total cells. (D) Quantitative immunofluorescence of miR-21 in TI and TME cell compartments. (E) Quantitative immunofluorescence intensity of miR-21 in CD68+ cells in TI and TME cell compartments. (F) Analysis of the percentage of miR-21+ Cd68+ of total miR-21+ cells in the 3 Yale cohorts
independently and combined. (G) Representative cytokeratin immunostaining, miR-21 FISH, and CD68 immunostaining of a random spot of YTMA250.
Dashed lines delimit TI (cytokeratin-enriched areas) from TME. Arrowheads no. 1 and no. 2 indicate cytoketatin+ cells in TI with high or low miR-21 intensity, respectively. Arrows no. 3 and no. 4 indicate CD68+ cells in TME with high or low miR-21 intensity, respectively. Arrows no. 5 and no. 6 indicate CD68+
cells in TI with high or low miR-21 intensity, respectively. Scale bar: 100 μm. (H–J) Kaplan-Meier OS survival curves of patients with NSCLC in a combined
analysis of 3 Yale cohorts; patients were stratified by the top tertile of normalized double-positive cell counts (miR-21+ CD68+) in (H) TI, (I) TME, and (J)
total cells. (A–C and H–J) Kaplan–Meier survival curves compared by log-rank test. *P < 0.05.

scriptional dysregulation between each genotype and highlighted
the similar expression patterning found among biological replicates in each group (Figure 5A). Ingenuity pathway analysis (IPA)
of both up- and downregulated genes (Figure 5B) in miR-21–/– TAMs
identified gene signatures that favor cytokine-mediated commu5522
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nication between innate and adaptive immune cells, Th1 pathway,
and a proinflammatory gene profile (Figure 5B). Conversely, a
metabolic gene pattern, that in macrophages is linked to antiinflammatory functions, and a Th2 gene signature were diminished in miR-21–/– TAMs (Figure 5B). Similarly, the top overrepre-
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Figure 5. Differential gene expression of TAMs in the absence of miR-21 expression. (A) Heatmap of hierarchical clustering log2-transformed gene
expression values of the significantly differentially expressed genes (1,035) between miR-21–/– and WT TAMs (n = 4) isolated from s.c. LLC tumors. Colors
displayed by row minimum and maximum values: yellow, higher expression; blue, lower). (B) IPA analysis of both up- (left) and down- (right) regulated
genes in LLC TAMs lacking miR-21 expression vs. WT TAMs. (C) IPA of overrepresented disease or function categories upregulated (left) and downregulated
(right) as a result of miR-21 deletion in TAMs of LLC tumors. (D–G) Heatmaps of significantly differentially expressed genes that contribute to (D) communication between innate and adaptive immune cells (E), Th1 pathway (F), IL-12 signaling in macrophages (G), and PPARa/RXRa activation.

sented disease and function categories pointed to an increased
function of macrophages as antigen-presenting cells that promote
activation of T lymphocytes (Figure 5C). Alternatively, gene signatures related to tumor growth and the regulation of blood ves-

sel formation were downregulated (Figure 5C). Heatmaps with
the list of regulated genes within these pathways and additional
relevant functions are depicted in Figure 5, D–G and Supplemental Figure 3, B–D. Among the differentially expressed genes, Th1jci.org   Volume 129   Number 12   December 2019
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promoting and tumor- suppressive cytokines such as Il27 and Il12
(36, 37) and the costimulatory molecules (38), Cd86 and Cd40, were
upregulated in miR-21–/– TAMs (Supplemental Figure 3E). Moreover, we found increased expression of proinflammatory mediators
including Tnf and Cxcl10 and Cxcl9 (Supplemental Figure 3E).
IL-12 is a reported target of mir-21 (15) and a strong inducer of
Th1 responses, with demonstrated antitumor activity (37) that is
produced by different immune cells including macrophages. The
increased levels of Il12 found in miR-21–/– TAMs are consistent
with lost miR-21–mediated targeting. To identify miR-21/mRNA
associations relevant to TAM pathophysiology, we examined
global correlation patterns between significantly upregulated
genes in miR-21–/– TAMs and miR-21 predicted target genes (Figure 6A). We used a combination of 4 microRNA prediction algorithms and selected genes that were predicted by at least 2 prediction methods. Among the 321 significantly upregulated mRNAs,
65 were predicted targets of miR-21 (Figure 6A). Together, they
represented approximately 20% of the significantly upregulated
genes found in miR-21–/– TAMs. These 65 significantly upregulated and predicted targets of miR-21 were used as a data set for
network analysis using the IPA Regulator Effects algorithm (Figure 6B). Downregulation of miR-21 was predicted as an upstream
regulator, providing confidence of the predicted regulatory network generated. Among the predicted upstream regulators, we
found IL-21, IFNA, and IFNG, factors reported to have antitumor
effects in a variety of murine experimental tumor models (39–41).
The model also predicts IL-1B, a canonical proinflammatory cytokine with antitumor roles (42), as an upstream regulator. The
anticipated impact of the molecular expression changes showed
an increase in downstream functions involved in inflammatory
responses as well as the activation and homeostasis of leukocytes. These data indicate that miR-21 depletion in TAMs causes
a global rewiring of their transcriptional regulatory network that
is skewed toward a proinflammatory phenotype and the promotion of an antitumoral immune response (5, 42, 43). Proinflammatory stimulation of miR-21–/– BMDMs revealed a significant
upregulation of proinflammatory gene signature, including Il12,
Tnf, and Cxcl10 compared with WT BMDMs (Supplemental Figure 3F). These findings are in agreement with previous published
data (10, 16) and support the idea that miR-21 deficiency primes
macrophages to develop a proinflammatory program (43). In vivo,
this translates to an antitumor phenotype when it happens in conjunction with Th1 immune response (5, 42). Interestingly, a proinflammatory phenotype of TAMs in patients with NSCLC has been
positively associated with survival time (44).
Increased IL12 in miR-21–deficient TAMs improves cytotoxicity
of CD8+ T cells. Consistent with the TAM profiling data, we found
that tumors from miR-21–/– mice had a higher percentage of IL-12+
and TNF+ TAMs (Figure 7, A and B, left panels) and also had higher
levels of IL-12 and TNF (Figure 7, A and B, right panels). Similar
results were observed in the tumors of WT mice transplanted with
miR-21–/– BM (Figure 7, C and D). We also found increased levels
of costimulatory molecules CD40 and CD86 (Figure 7E) linked to
enhanced macrophage antitumor activity (38). These data, together with the overall transcriptome signature exhibited by miR-21–/–
TAMs, suggest that these cells could participate in enhancement
of cytotoxic T-lymphocyte (CTL)–dependent cell death (45–47).
5524
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Increased intracellular levels of GZMB and higher levels of
extracellular LAMP1 (CD107a) in tumor-infiltrated CD8+ T cells
indicate better targeting and killing capacity of cancer cells by
CTLs (48). We found that CD8+ T cells within the tumors of mice
transplanted with miR-21–/– BM had higher levels of GZMB than
their WT counterparts (Figure 7, F and G) and enhanced degranulation status (Figure 7, H and I), as indicated by the larger number of
CD8+ T cells with surface expression of CD107a (48). This finding
is in agreement with the increased cell death observed in tumors
of miR-21–/– or WT mice transplanted with miR-21–/– BM. However,
the phenotype observed in CD8+ TILs could be mediated by the
absence of miR-21 expression in these cells. Thus, we analyzed
GZMB levels in CD8+ T cells isolated from the Peyer’s patches of
healthy adult WT or miR-21–/– mice because in healthy and unchallenged mice, CD8+ T cells from Peyer’s patches express high levels
of GZMB (49). We did not find differences in GZMB levels (Supplemental Figure 3G). Additionally, naïve splenic CD8+ T cells of
miR-21–/– mice activated by anti-CD3 Ab for 3 and 6 days exhibited
no difference in intracellular levels of GZMB (Supplemental Figure 3H) compared with WT controls. These results indicate that
the absence of miR-21 in CD8+ T cells does not affect cell-intrinsic
levels of GZMB and that additional mechanisms account for the
observed differences in CD8+ TILs from miR-21–/– mice.
To test whether the increase of GZMB and CD107a in CD8+
TILs of miR-21–/– mice leads to more CTL activity, we isolated
CD8+ TILs from WT or miR-21–/– tumors and immediately cultured
them with LLCs to monitor their killing capacity. CD8+ TILs isolated from miR-21–/– mice were more effective at reducing proliferation and increasing the number of apoptotic (annexin V+) target
cells (Figure 7, J and K), indicating that miR-21 deficiency in nonCD8+ cells within the TME improves CTL activity.
IL-12, a potent inducer of CTL activity in CD8+ T cells (37),
was increased in TAMs of miR-21–/– mice or WT mice transplanted with miR-21–/– BM (Figure 7, A and C). Thus, we hypothesized
that increased IL-12 in miR-21–/– TAMs was responsible for the
increased GZMB levels. Thereby, WT splenic CD8+ T cells were
isolated and activated with an anti-CD3 Ab and incubated with
conditioned media obtained from miR-21–/– or WT TAMs (Figure
7L). Conditioned media from miR-21–/– TAMs led to higher levels of
GZMB than media obtained from WT TAMs. Furthermore, a neutralizing anti–IL-12 Ab blunted this effect (Figure 7L). Altogether,
these data suggest that IL-12 from miR-21–/– TAMs participates in
the improved T-cell responses observed in mice transferred with
miR-21–/– BM and thus contributes to the increased tumor cell
death observed in these animals, consistent with the enhanced
antitumor immune response mediated by miR-21–/– TAMs.
Increased CXCL10 in miR-21–deficient TAMs mediates angiostatic
effects within the LLC tumors. Reduced vascularization was another
outstanding phenotype observed in tumors of mice transplanted
with miR-21–/– BM. mir-21–/– TAMs exhibited a gene signature associated with decreased blood vessel formation. In addition to Il12, miR21–/– TAMs exhibited increased mRNA levels of Cxcl10 and Cxcl9.
IL-12 in tumors negatively regulates the tumor vasculature (50).
This effect is associated with IFN-inducible production of CXCL10
and CXCL9, angiostatic chemokines that have been described to
halt tumor progression by inhibiting EC proliferation and differentiation into capillary structures (51). Immunofluorescent staining
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Figure 6. miR-21 depletion in TAMs causes a global rewiring of their transcriptional regulatory network that is skewed towards a pro-inflammatory
phenotype and the promotion of an antitumoral immune response. Global correlation pattern between significantly upregulated genes in miR-21–/– TAMs
and miR-21 predicted target genes. (A) Venn diagram depicting the correlation between miR-21 predicted targets (predicted ≥ 2 algorithms out of 4) vs.
upregulated mRNAs in miR-21–/– TAMs (FC >1.5), P ≤ 0.005 Benjamini-Hochberg False Discovery Rate. The 65 genes of the miR-21–mRNA correlation study
are depicted in the box below, including IL-12, a validated target of miR-21. (B) IPA network analysis of Regulator Effects algorithm of the 65 predicted
targets of miR-21 significantly upregulated in miR-21–/– TAMs.

demonstrated that CXCL10 was significantly increased in CD68+
TAMs from WT mice transplanted with miR-21–/– BM (Figure 8A).
Moreover, tumor ECs (TECs) isolated from these mice showed
reduced numbers of Ki-67+ cells compared with their control counterparts (Figure 8B), indicating diminished proliferation. These
results indicate that absence of miR-21 induces the expression and

production of IL-12 and CXCL10 in TAMs. This can explain, at least
in part, the increased tumor cell death and reduced neovascularization, leading to an overall reduction of tumor growth.
Conditional deletion of miR-21 in macrophages reduces tumor
growth by promoting CTL activity and diminishing the proliferative
phenotype of tumor-associated vasculature via increased IL-12 and
jci.org   Volume 129   Number 12   December 2019

5525

RESEARCH ARTICLE

The Journal of Clinical Investigation  

Figure 7. miR-21 deletion in TAMs leads to improved immune response to tumors via increased IL-12. Flow cytometry analysis (A) Left: % of TAMs
expressing IL-12 in s.c. LLC tumors of WT or miR-21–/– mice. Right: IL-12 levels (MFI) (n = 4). (B) Left: % of TAMs expressing TNF. Right: TNF levels. (C and
D) IL-12 and TNF (as in A and B) of s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM, (n = 6). (E) % of TAMs expressing CD40 (left) or CD86
(right), (n = 6). (F) Left: Representative plots of GZMB in CD8+ TILs of s.c. LLC tumors of WT or miR-21–/– mice. Middle: % of CD8+ TILs expressing GZMB.
Right: GZMB levels (n = 3). (G) % of CD8+ TILs expressing GZMB of s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM (n = 6). (H) Left:
Representative plots of extracellular CD107a levels in CD8+ TILs of s.c. LLC tumors of WT and miR-21–/– mice. Right: % of CD8+ TILs expressing extracellular
CD107a (n = 3). (I) % of CD8+ TILs expressing extracellular CD107a in s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM (n = 6). (J) Alive LLCs,
cultured for 12 hours with CD8+ TILs from LLC tumors of WT or miR-21–/– mice at indicated effector:target ratios (n = 4). (K) % of annexin V+ LLCs, cultured
(12 hours) with CD8+ TILs from LLC tumors of WT or miR-21–/– mice (n = 4). (L) GZMB expression by CD8+ splenocyte T cells activated with plate-bound anti–
CD3-Ab and incubated with conditioned media from cultured WT or miR-21–/– TAMs plus neutralizing anti–IL-12 or IgG Ab (n = 4). Results are mean ± SEM.
*P < 0.05. (A–I and K) Mann-Whitney U test. (J and L) Two-way ANOVA with Bonferroni correction. (A, B, F, and H). Representative experiments out of 3 or
(C–E, G, I, and J–L) out of 2 with similar results.
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Figure 8. miR-21 deletion in TAMs leads decreased angiogenesis via
increase of CXCL10. (A) Left: Representative images of immunofluorescence costaining of CD68 and CXCL10 in frozen sections from s.c.
LLC tumor of WT mice transplanted with WT or miR-21–/– BM cells.
Right: Quantification of CXCL10 intensity per CD68+ cell (n = 4). (B)
left: Representative flow cytometry plot of CD45–CD31+Ki-67+ cells
from s.c. LLC tumors of WT mice transplanted with WT or miR-21–/–
BM cells. Right: Average of % CD31+ Ki-67+ cells (n = 6). Results are
mean ± SEM. *P < 0.05. Mann-Whitney U test. Representative
experiments out of 2 with similar results. Scale bars: 70 μm.

CXCL10 production. To more specifically ascertain whether the
observed effects were a result of deletion of miR-21 in macrophages, we used LysMCre;miR-21fl/fl mice. LysMCre mice allow for
both fairly specific and highly efficient (83%–98%) Cre-mediated
deletion of mature macrophages (52).
Deletion of miR-21 in the macrophages also led to the development of smaller tumors when compared with control mice (miR21fl/fl) (Figure 9, A and B). LLC tumors from LysMCre;miR-21fl/fl
mice did not have decreased TAM infiltration; however, their MHCII
expression was increased (Figure 9C). Tumors from LysMCre;
miR-21fl/fl mice showed increased levels of cell death (Figure 9D),
and although the overall number of CD8+ T cells was not affected,
they had higher levels of GZMB and extracellular CD107a (Figure
9E). Tumors from LysMCre;miR-21fl/fl mice also exhibited reduced
neovascularization (Figure 9F), which was associated with reduced
proliferating TECs (Figure 9G) and an increased percentage of
TUNEL+ CD31+ TECs(supplemental Figure 4A). This effect could
also be attributable to the higher levels of CXCL10 found in CD68+
macrophages of these tumors (Figure 9H).
To ascertain whether these effects on tumor growth were due
to LLCs being grown in a non–organ-specific microenvironment,
we performed orthotopic implantation of the isogenic LL/2 RedFluc murine LLC-derived cell line (Figure 10, A and B) or isogenic
B16 melanoma murine skin cancer cell line (Supplemental Figure
4, B and C) into LysMCre;miR-21fl/fl and analyzed tumor growth.
Deletion of miR-21 in macrophages led to the development of
smaller tumors in these 2 different orthopic models. When cancer
cells were implanted in an organ-specific microenvironment, the
effect of miR-21 deficiency in macrophages was exacerbated (Figure 9, A and B, and Figure 10B).
Some reports have described LysM-mediated Cre recombination in DCs, although efficiencies range from 5% to 50% depend-

ing on the tissue and the subpopulation of DCs analyzed (53, 54).
Given that tumoral DCs have been described to be necessary for
CTL activation (55, 56), we analyzed LysMCre-mediated deletion of miR-21 in TAMs vs. tumor DCs. As shown in Supplemental Figure 4D, TAMs from s.c. LLC tumors of LysMCre;miR-21fl/fl
showed efficient reduction of mR-21 levels when compared with
TAMs isolated form control miR-21fl/fl mice. However, the expression of miR-21 in DCs isolated from LysMCre;miR-21fl/fl of miR-21fl/fl
tumor-bearing mice was unaffected. Thus, the phenotype is not
attributable to the deletion of miR-21 in tumor DCs.
To better understand the interaction of miR-21–deficient
macrophages with CD8+T cells in the context of the TME, we performed single-cell RNA-Seq in sorted CD45+ cells from the tumors
of miR-21fl/fl or LysMCre;miR-21fl/fl mice. We first used unsupervised
clustering to generate t-distributed stochastic neighbor embedding (t-SNE) plots that separated the cells into distinct groups
(Figure 11, A and B). Representation of t-SNE plots (Figure 11,
overlay colored by sample) did not reveal overall outstanding differences in cell populations. The same colored cells were clustered
together in the combined sample (Figure 11B). We identified and
classified 7 major cell types: CD8+T cells, CD4+ T cells, NK cells,
granulocytic MDSCs, monocytic MDSCs, DCs and macrophages/
monocytes (see featured plots of selected marker gene overlays
in Supplemental Figure 5A). Within the macrophages, 8 different
clusters were detected. Based on gene markers of existing literature (57), proangiogenesis and proinflammatory macrophages
were classified (Supplemental Figure 5, A and B). Within the different macrophage/monocyte clusters, the expression of canonical differentiation markers largely overlapped (Supplemental
Figure 5B). All remaining macrophage cluster types failed to pass
the classification threshold for any specific macrophage type and
stayed as “unassigned.” Because CD8+ T cells were unequivocally
jci.org   Volume 129   Number 12   December 2019
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Figure 9. miR-21 expression by TAMs promotes tumor progression by inducing CD8+ T-cell suppression and angiogenesis. (A–H) Tumor analysis of
miR-21fl/fl and LysMCre;miR-21fl/fl mice with s.c. injection of LLCs (n = 7). LLC tumor volume (A), final tumor weight (B). (C) Left: Average % of TAMs of s.c.
LLC tumors. Right: MHC II surface levels in TAMs (average MFI) (n = 6 out 7 randomly selected). (D) Left: Representative images of TUNEL and DAPI staining of cross sections of s.c. LLC tumors. Right: Quantification of % DAPI+ TUNEL+ cells (n = 7). (E) Flow cytometry analysis of CD8+ TILs in s.c. LLC tumors.
Average % of CD8+ TILs (left), % of CD8+ TILs expressing GZMB (middle) and % of CD8+ TILs with extracellular CD107a (right) (n = 7). (F) Representative
images of CD31 staining of cross sections of s.c. LLC tumors. Right: Quantification of CD31+ vessel-like structures (n = 7). (G) Average % CD31+ Ki-67+ cells
of s.c. LLC tumors (n = 7). (H) Left: Representative images of immunofluorescence costaining of CD68 and CXCL10 in frozen sections of s.c. LLC tumors.
Right: Average quantification of CXCL10 intensity per CD68+ cell (n = 3, out of 7 randomly selected). Results are mean ± SEM. *P < 0.05. (A) Two-way
ANOVA (time and genotype) with Bonferroni correction, #P < 0.05 individual comparisons. (B–H) Mann-Whitney U test. (A–H) Representative experiment
out of 2 with similar results. Scale bars: 70 μm.

identified, we analyzed the changes in gene expression in CD8+
TILs (with intact miR-21) that were either in an immune infiltrate
environment mostly made up of macrophages expressing miR-21
(miR-21fl/fl) or not expressing miR-21 (LysMCre;miR-21fl/fl). Figure
11C shows a dot plot analysis of differentially expressed genes in
CD8+T cells of the tumor immune infiltrate of miR-21fl/fl or LysMCre;
miR-21fl/fl mice. Interestingly, the proportion of cells with high
expression of genes associated with an activated and cytotoxic
phenotype, including Il12rb2, Cd69, Ifng, Ccl4, Ccl3, Cxcl10, and
5528
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several granzyme coding genes, was increased in CD8+ TILs of the
tumor immune infiltrate of LysMCre;miR-21fl/fl mice. IPA analysis
of this set of genes showed an enrichment of gene signatures that
promote the communication between innate and adaptive immune
cells, as well as IL-12 signaling and Th1 immune responses (Figure
11D). Prediction network analysis of these regulated genes showed
IL-12 as a potential upstream regulator, while degranulation and
cytotoxicity of T cells were predicted as downstream functions of
these gene expression changes (Figure 11E). Importantly, block-
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Figure 10. miR-21 expression by TAMs promotes tumor progression in lung tumors. (A and B) Bioluminescence imaging and final tumor weight of lung
tumors generated by LL/2Red Luc injected orthotopically into the lungs of miR-21fl/fl and LysMCre;miR-21fl/fl mice. For tumor weight in B, remaining healthy
lung tissue was removed. (n = 5 and 6, respectively). Results are mean ± SEM. *P < 0.05. (A) Two-way ANOVA (time and genotype) with Bonferroni correction, #P < 0.05 individual comparisons. (B) Mann-Whitney U test. Representative experiment out of 2 with similar results. Scale bars: 70 μm.

ade of IL-12 and CXCL10 in tumor-bearing LysMCre;miR-21fl/fl
mice produced an increase in tumor growth as compared with
LysMCre;miR-21fl/fl mice treated with an isotype control (Figure 12,
A and B). Furthermore, we observed a reduction in the expression
of GZMB in CD8+ TILs when IL-12 and CXCL10 were neutralized
in LysMCre;miR-21fl/fl mice (Figure 12C), as well as an increase in
neovascularization (Figure 12D). On the whole, our results provide evidence that the decreased tumor growth, improved CTL
response, and decreased neovascularization observed in animals
lacking miR-21 in TAMs is mediated, at least in part, by increased
IL-12 and CXCL10.
Antagonism of miR-21 in macrophages reduces tumor progression
even when miR-21 is not expressed in cancer cells. Given the desirable
outcomes that miR-21 deficiency in macrophages produces, we
aimed to specifically inhibit miR-21 in macrophages during tumor
progression. We took advantage of a pHLIP, which is a carrier peptide that under acidic conditions can insert directionally across cell
membranes and thereby translocate otherwise membrane-impermeable cargo molecules into cells via a nonendocytic route (58).
Given the acidic conditions found in solid tumors, pHLIP has been
shown to home to a variety of tumors when administered systemically (59). pHLIP has been coupled to antisense nucleic acid analogues consisting of peptide nucleic acids (PNAs), to create delivery vectors to successfully silence tumor miRNAs (60). The acidic
environment found in the tumor has been largely attributed to the
high glycolytic rate of tumor cells (61). TAMs have also activated
aerobic glycolysis and thus contribute to a local acidification within
the TME (62). We wondered whether pHLIP would also efficiently
accumulate in TAMs in addition to tumor cells. Enhanced insertion
of pHLIP into a variety of cells has been shown under acidic conditions in vitro (58). However, internalization of pHLIP by different
cell types within the tumor has not been reported. Thus, we s.c.
implanted eGFP-LLCs, and 2 weeks, later mice were injected with
pHLIP Variant 3 (Var3) conjugated with fluorescent Alexa546 (63).
Single cells of the tumor were isolated, and Alexa546 fluorescence
was analyzed via flow cytometry. We found that in addition to cancer cells (eGFP LLCs), the fluorescent signal from pHLIP Var3AF546 was also detected in TAMs (Supplemental Figure 6, A–C).
Although the percentage of cancer cells that incorporated pHLIP
Var3-AF546 was higher (Supplemental Figure 6A), the cell-associated fluorescence was greater in TAMs (Supplemental Figure 6, B

and C). Interestingly, splenic macrophages did not show any pHLIP
Var3-AF546 cell incorporation. When compared with other cells of
the tumor immune infiltrate, also in an acidic microenvironment,
TAMs seem to be more efficient at incorporating pHLIP Var3AF546 because a greater number of cells showed a higher amount
of inserted peptide when compared with CD4+ or CD8+ T cells and
DCs (Supplemental Figure 6F). Interestingly, nonimmune cells of
the TME, including ECs did not efficiently internalize pHLIP when
compared with CD68+ macrophages within the tumor (Supplemental Figure 6F). These data indicate that pHLIP is an efficient
way to target not only cancer cells but also TAMs.
We then assessed the therapeutic antitumor efficacy of pHLIP
anti–miR-21 PNA in vivo. The PNAs were also tagged with TAMRA
for visualization. Intravenous administration of pHLIP anti–miR-21
to mice with orthotopic and heterotopic lung cancer tumors resulted in a significant reduction in tumor growth when compared with
mice injected with pHLIP anti–miR-mismatch control (Supplemental Figure 8, A and B, and Figure 13A). Furthermore, enhanced
delivery (TAMRA fluorescence) to macrophages within the tumor
was detected by flow cytometry and by immunofluorescence in
CD68+ macrophages (Supplemental Figure 6, D and E, respectively). Despite the fact that DCs also became glycolytic upon activation (64), we only found a small proportion of DCs that showed low
levels of incorporation of pHLIP Var3-AF546 (Supplemental Figure
6, A–C) or pHLIP anti–miR-21-TAMRA (Supplemental Figure 6, D
and E). This was not sufficient to reduce miR-21 levels in DCs or
affect miR-21 target expression (Supplemental Figure 6G).
To avoid targeting cancer cells expressing miR-21, we used
CRISPR/Cas9-mediated genome editing to KO miR-21 from
LLC cells (miR-21–/– LLCs) (Supplemental Figure 7). The effect of
pHLIP anti–miR-21 was assessed in mice bearing miR-21–/– LLC
tumors (Figure 13B). pHLIP anti–miR-21 administration still
reduced tumor burden in mice bearing miR-21–/– LLC tumors, suggesting that targeting miR-21 in TAMs is sufficient to efficiently
diminish tumor growth. Moreover, increased tumor cell death
and reduced neovascularization were also observed (Figure 13, C
and D). mRNA levels of miR-21 targets such as Il12, Tnf, or Cxcl10
were increased in sorted TAMs from miR-21–/– LLC tumors that
were administered pHLIP anti–miR-21 (Figure 13E), indicating
efficient miR-21 inhibition in TAMs. We also observed improved
T-cell responses as indicated by increased GZMB and degranulajci.org   Volume 129   Number 12   December 2019
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Figure 11. Increased cytotoxic program and phenotype in CD8+ TILs is the result of miR-21 deletion in macrophages. (A) Overlaid t-SNE plots colored by
sample of CD45+ cells isolated from s.c. LLC tumors of miR-21fl/fl and LysMCre;miR-21fl/fl mice. (B) Recolored t-SNE plot based on matching results for the
combined dataset distinct groups of cells separated and manifested. See feature plots of select marker gene overlays in Supplemental Figure 2A. (C) Dot
plot analysis of differentially expressed genes in CD8+T cells of s.c. LLC tumor immune infiltrate of LysMCre;miR-21fl/fl or LysMCre;miR-21fl/fl mice. (D) IPA
analysis of set of genes differentially regulated in CD8+ T cells from s.c. LLC tumors of LysMCre;miR-21fl/fl versus miR-21fl/fl mice. Dot size represents the
fraction of cells expressing the gene, and red color represents a greater than 1.5-fold gene expression among expressing cells. (E) IPA network analysis
using Regulator Effects algorithm of gene set differentially regulated in CD8+ T cells from LLC tumors of LysMCre;miR-21fl/fl versus miR-21fl/fl mice.

5530

jci.org   Volume 129   Number 12   December 2019

The Journal of Clinical Investigation  

RESEARCH ARTICLE

Figure 12. Neutralization of IL-12 and CXCL10 decreases tumor growth, improved CTL response, and decreased neovascularization in animals lacking miR21 in macrophages. Tumor analysis of miR-21fl/fl and LysMCre;miR-21fl/fl mice with s.c. injection of LLCs (n = 6) and treated with 200 μg of anti–IL-12 + 100 μg
of anti-CXCL10 neutralizing antibodies or 300 μg of isotype control on the indicated days. LLC tumor volume (A), final tumor weight (B). (C) Flow cytometry
analysis of CD8+ TILs. Left: Average % of CD8+ TILs expressing GZMB, Right: GZMB levels (average MFI) (n = 6). (D) Representative images of CD31 immunostaining of cross sections. Right: Quantification of CD31+ vessel-like structures (n = 6). Results are mean ± SEM. *P < 0.05. (A) Two-way ANOVA (time and
genotype) with Bonferroni correction. (B–D) Kruskal-Wallis test. (A–D) Representative experiment out of 2 with similar results. Scale bars: 70 μm.

tion in CD8+ TILs (Figure 13F). Furthermore, increased levels of
CXCL10 in CD68+ macrophages of these tumors was associated
with reduced CD31+ capillary structures (Figure 13G).
Taken together, these results show that targeting miR-21 in
macrophages promotes an antitumoral immune response and an
overall proinflammatory angiostatic function that results in a significant reduction in tumor growth.

Discussion

In this study, we have used a variety of different mouse models to
assess how miR-21 in noncancerous cells of the TME contributes
to tumor progression. Cancer initiation and progression has been
historically defined by the behavior of cancer cells, including regulation by miRNAs, which have an impact on many of the autonomous functions of cancer cells to either promote or suppress tumor
growth (1). Importantly, miRNAs in cells from the TME have also
emerged as key players involved in the development and progression of cancer (5–7, 65).
Our results using syngeneic heterotopic and orthotopic lung
cancer models demonstrate that miR-21 expression in noncancerous cells plays an important role in tumor progression, in agreement with reports using other models (24, 25). However, the existing literature fails to fully elucidate the cell compartment of the
TME in which miR-21 primarily contributes to tumor progression,
often relying on in vitro systems or approaches that globally target
miR-21 in a non–cell/tissue-specific manner (19–25, 31).
Within the TME, miR-21 has been reported to be increased in
many types of cancer (22, 27, 31, 66), and this increase was linked
to tumor progression. Our data, in 3 cohorts of patients with stage

I NSLC show that high expression of miR-21 in the nontumor cells
of the TME is significantly associated with reduced overall survival. In agreement with these findings, a recent report shows that
increased expression of miR-21 in the TME, but not in cancer cells,
was associated with a poor prognosis for patients with lung adenocarcinoma (31). This effect was linked with increased expression
of miR-21 in cancer-associated fibroblasts (CAFs) (31), similar to
what has been reported in pancreatic and colorectal tumors (21–
23). However, the underlying mechanisms of cancer-associated
fibroblast–miR-21 promoting tumor growth were only investigated in vitro. We show that the expression of miR-21 in infiltrated
immune cells, not stromal cells, is responsible for promoting
tumor growth. This finding was supported by the decreased tumor
growth in WT mice adoptively transferred with miR-21–/– BM,
whereas reverse BMT (WT BM to miR-21–/– recipients) produced a
converse effect. This observation was in agreement with a recent
study that also used BM adoptive transplant to show that deletion
of miR-21 in immune cells reduces tumor growth (25). Elevation of
miR-21 levels has been observed in MDSCs directly derived from
BM cells that were stimulated with GM-CSF and IL-6, as well as
MDSCs from tumor-bearing mice (19), and in vitro overexpression or inhibition of miR-21 in BM cells altered MDSC expansion
(19). However, within the tumor infiltrate of miR-21–/– or WT mice
adoptively transferred with miR-21–/– BM, we did not find differences in the proportion of monocytic or granulocytic MDSCs
when compared with controls. This finding indicates that the in
vivo absence of miR-21 in MDSCs does not have a major effect on
this population. Similarly, when we analyzed TILs, we did not find
differences in the percentage of IFNG expressing CD4+ or CD8+
jci.org   Volume 129   Number 12   December 2019
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Figure 13. Targeting macrophage miR-21 leads to improved T-cell responses and decreased angiogenesis. (A) Tumor progression in WT mice injected
s.c. with 106 LLCs in the dorsal flank and treated with 1 mg/kg pHLIP anti–miR-21 or pHLIP anti–miR-21-mismatch control on indicated days (n = 6). (B)
Tumor progression in WT mice injected s.c. with 106 with miR-21–/– LLC and treated with 1 mg/kg pHLIP anti–miR-21 or pHLIP anti–miR-21-mistmatch on
indicated days (n = 6). (C) Representative images of TUNEL and DAPI staining of cross sections of miR-21–/– LLC tumors of WT mice treated as in B. Right:
Quantification of % DAPI+ TUNEL+ cells (n = 4 out of 6 randomly selected). (D) Representative images of CD31 staining of cross sections of miR-21–/– LLC
tumors of WT mice treated as in B. Right: Quantification of CD31+ vessel-like structures (n = 4 out of 6 randomly selected). (E) qRT-PCR analysis of relative
mRNA levels of validated or predicted targets of miR-21 (Il12, Tnf, and Cxcl10) in sorted TAMs (CD45+ CD11b+ MHC II+ F4/80+) of miR-21–/– LLC tumors of WT
mice treated as in B (n = 3 out of 6 randomly selected). (F) Right: Flow cytometry analysis of average % of CD8+ TILs expressing GZMB. Left: % CD8+ TILs
with extracellular CD107a in miR-21–/– LLC tumors of WT mice treated as in B (n = 4 out 6 randomly selected). (G) Left: Representative images of immunofluorescence costaining of CD68 and CXCL10 in frozen sections of miR-21–/– LLC tumors of WT mice treated as in B. Right: Average of quantification of
CXCL10 intensity per CD68+ cell (n = 4 out 6 randomly selected). Results are mean ± SEM. *P < 0.05. (A and B) Two-way ANOVA (time and genotype) with
Bonferroni correction, #P < 0.05 individual comparisons. (C–G) Mann-Whitney U test. Scale bars: 70 μm.
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T cells, in agreement with a recent report (25). In other settings,
miR-21 has been shown to regulate cell-autonomous T-cell function (67, 68). In the context of tumor progression, a report showed
that absence of miR-21 reduced the proliferation of both CD4+ and
CD8+ cells and their cytokine production, thus accelerating the
growth of grafted tumors (24). In this case, growth of an implanted S180 mouse cancer cell line was analyzed in miR-21 floxed
expressing the global Cre driver. S180 cells have been shown to
grow in multiple inbred mouse strains due to β2-microglobulin
deficiency, MHC class I destabilization, and impaired recognition
by host CTLs (69). In this setting and without using a syngeneic
mouse model and/or conditional deletion of miR-21 in T cells, it
was concluded that miR-21 expression in T cells was protective
against tumor growth (24).
Several studies have described correlations between macrophage number, location, and phenotypic characteristics and
clinical outcomes (70). In our human TMAs, we found that high
expression of miR-21 in CD68+ macrophages within the TME
compartment had a negative impact in patient disease-specific
survival and shows the relevance of miR-21 in macrophages for
tumor progression. In line with miR-21 being the most abundant miRNA in macrophages (10), we found that within the LLC
tumors, miR-21 is highly expressed in TAMs compared with the
rest of the tumor immune infiltrate. Because conflicting results
have been reported regarding the role of miR-21 in regulating the
inflammatory responses of macrophages (10, 13–15, 17, 18, 43), we
specifically focused on how miR-21 regulates the gene expression
and functions of TAMs. miR-21 deficiency in TAMs produced a
global rewiring of their transcriptional regulatory network that is
skewed toward a proinflammatory phenotype and the promotion
of an antitumoral immune response. Importantly, we show that
selective deletion of miR-21 in macrophages in a heterotopic and
orthotopic model of lung cancer mimicked the effects of global
or hematopoietic loss of miR-21, with smaller tumors, increased
cell death, and reduced neovascularization. Moreover, we found
increased GZMB and degranulation of CD8+ TILs, indicating
increased CTL activity and heightened killing capacity, consistent with the higher levels of cell death within the tumors of
LysMCre;miR-21fl/fl mice. These findings support the report of Baer
and colleagues who showed that disruption of miRNA processing
in TAMs, by LysM-Cre–mediated deletion of Dicer1, leads to the
development of smaller LLC tumors and improved CTL activity
(5). This study highlights how the loss of mature miRNAs in TAMs
during tumor progression leads to increased classically activated
TAMs, improved CD8 response, and decreased CD8 suppression,
which was associated with higher expression of CXCL10, CD86,
and CXCL9 in the tumors (5). In fact, because miR-21 is highly
expressed in macrophages (10), many of these changes could be
attributed to the loss of expression of miR-21 after Dicer1 deletion.
A recent report using a B16 tumor model suggested that mice
receiving miR-21–deficient BM had higher numbers of “M1”
TAMs with tumoricidal polarization, whereas miR-21 deficiency in
T cells reduced their ability to produce proinflammatory cytokines
and cytolytic granules (25). On the contrary, our data indicate that
CD8+ TILs from miR-21–/– mice have increased GZMB expression
and killing capacity. However, the increased GZMB expression is
not due to miR-21 deletion in these cells because LLC tumors from
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LysMCre;miR-21fl/fl also showed increased levels of cell death and
their CD8+ T cells (expressing miR-21). They also had higher levels
of GZMB and extracellular CD107a, suggesting that the absence
of miR-21 in TAMs can influence other cells within the TME.
Our present results indicate that the observed changes in the
levels of chemokines and cytokines in miR-21–deficient TAMs
are critical for CTL activation and antitumor activity. Specifically, we found that increased IL-12 in miR-21–/– TAMs is responsible
for the increased GZMB levels independent of miR-21 expression
in CD8+ T cells. This finding was supported by our single-cell
RNA-Seq analysis, where we analyzed the changes in gene expression in CD8+ TILs from tumors in which TAMs lacked miR-21. In
LLC tumors from LysMCre;miR-21fl/fl mice, the CD8+ TILs exhibit
increased expression of genes associated with an activated and
cytotoxic phenotype, including Il12rb2, Cd69, Ifng, Ccl4, Ccl3,
Cxcl10, and several granzyme coding genes. These results provide
evidence that the improved CTL response is the result of miR-21
deletion in macrophages.
In addition to the effects on T-cell functions, the increased
levels of IL-12 in LysMCre;miR-21fl/fl mice could also play an
important role in regulation of tumor angiogenesis, as IL-12 has
been shown to negatively regulate tumor neovascularization (50).
This effect has been associated with IFN-inducible production of
CXCL10 and CXCL9 (51). Macrophages lacking miR-21 exhibited
an increased production of CXCL10, which binds to the CXCR3-B
receptor on endothelial cells, resulting in suppression of endothelial cell proliferation and differentiation into capillary structures
(51). CXCL10 selectively attracts Th1 cells and functions as a positive feedback loop in the Th1-driven antitumor immune response
(45). The tumors from LysMCre;miR-21fl/fl mice exhibited reduced
neovascularization, a reduced number of proliferating TECs, and
an increased percentage of TUNEL+ CD31+ TECs. Taken together,
our present work indicates that the absence of miR-21 in macrophages favors the formation of a tumor- suppressive microenvironment (45), characterized by increased expression of IL-12 and
CXCL10 that leads to improved CTL response, decreased neovascularization, and decreased tumor burden.
Macrophages are perhaps the most important immune cells
that infiltrate the tumor and affect its pathology (71, 72). Although
macrophages can show some antitumor activity (73), they mostly
promote a net protumor outcome because they have been shown
to be capable of dampening T-cell responses and stimulating
angiogenesis, among others actions (47, 74). This phenomenon,
which has been widely accepted, is promoted by tumor cells that
create a widespread tolerogenic environment through the release
of tumor-derived factors that promote the expansion and reprogramming of TAMs to block T-cell functions and promote several
protumor events. TAMs are recognized as an important target for
therapeutic intervention (75). Our data highlight the central role of
miR-21 in regulation of TAM activity and function regarding CTL
regulation and neovascularization. Thus, to determine whether
the high expression of miR-21 in TAMs may make it a likely target
for therapeutic intervention, we opted to use pHLIP anti–miR-21
PNA. pHLIP carriers coupled to antisense nucleic acid analogues
are delivery vectors that have been shown to successfully target
miRNAs in tumor cells (60, 76). Here, we show for the first time
that TAMs incorporate pHLIP as efficiently as tumors cell and
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strikingly more effectively than other cells of the TME. pHLIP
anti–miR-21 administration in WT mice reduced tumor burden
even under conditions where tumor cells lacked miR-21 expression. Importantly, CD8+ TILs showed increased GZMB expression and tumors had reduced neovascularization. Sorted TAMs
of pHLIP anti–miR-21 treated mice exhibited increased IL-12
and CXCL10 expression, similar to TAMs of LysMCre;miR-21fl/fl
mice. Thus, targeted inhibition of miR-21 in TAMs is sufficient to
increase CTL activity and decrease angiogenesis, thereby diminishing tumor growth.
Numerous studies have shown that within cancer cells, miR-21
acts as an oncomiR, and anti–miR-21 therapy (RG-012) is already
in the pipeline for clinical trials. Our findings demonstrate the critical role of miR-21 within TAMs for promoting tumor development,
indicating that targeting of miR-21 may have the added benefit of
improving CTL activity and limiting tumor angiogenesis through
its effects on TAMs. Our findings in human patients with NSCLC
suggest this may have a critical impact on patient outcomes. Finally, our results indicate that use of pHLIP targeted therapies allows
for effective targeting of both tumor cells and TAMs, while avoiding possible unintended effects on other tissues and organs.

Methods

Detailed information on experimental procedures and reagents is
provided in Supplemental Tables 1–3, Supplemental Figure 7, and
Supplemental Methods.
Mice. Experiments were conducted under the ethical guidelines and protocols approved by IACUC (Institutional Animal Care
and Usage Committee) in Yale University School of Medicine. WT
C57BL/6 or miR-21–/– (Mir21atm1Yoli/J, Jax no. 016856) mice were
purchased from The Jackson Laboratory. miR-21–/– mice were bred
with C57BL/6 mice for several generations in order to ensure they
were syngeneic and on C57BL/6 background. LysMCre;miR-21fl/fl on
C57BL/6 background mice were generated by breeding miR-21fl/fl
(Mir21tm1Mtm/Mmjax, Jax no. 36060) on C57BL/6 background with
LysMCre (Lyz2tm1(cre)Ifo, Jax no. 004781); miR-21fl/fl in C57BL/6 background were used as control counterparts.
Data and software availability. All RNA-Seq and single-cell RNASeq data were deposited in the NCBI’s Gene Expression Omnibus
database (GSE117697 and GSE118931).
Statistics. Data are presented as mean ± SEM. Statistical differences were measured using 1-way ANOVA or 2-way ANOVA with Bonfer1. Svoronos AA, Engelman DM, Slack FJ. OncomiR
or tumor suppressor? The duplicity of microRNAs
in cancer. Cancer Res. 2016;76(13):3666–3670.
2. Wang J, Chen J, Sen S. MicroRNA as biomarkers
and diagnostics. J Cell Physiol. 2016;231(1):25–30.
3. Suzuki HI, Katsura A, Matsuyama H, Miyazono
K. MicroRNA regulons in tumor microenvironment. Oncogene. 2015;34(24):3085–3094.
4. Hanahan D, Coussens LM. Accessories to
the crime: functions of cells recruited to
the tumor microenvironment. Cancer Cell.
2012;21(3):309–322.
5. Baer C, et al. Suppression of microRNA activity
amplifies IFN-γ-induced macrophage activation
and promotes anti-tumour immunity. Nat Cell
Biol. 2016;18(7):790–802.
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roni correction for multiple comparisons. Normality was checked using
the Kolmogorov–Smirnov test. A nonparametric test, Mann-Whitney
U, test or a Kruskal-Wallis test for multiple comparisons, was used
when data did not pass the normality test. For RNA-Seq analysis, we
used Benjamini-Hochberg False Discovery Rate. Survival curves were
generated by Kaplan–Meier analysis and tested for significance using
the Mantel-Cox log-rank test. A value of P ≤ 0.05 was considered statistically significant. Data analysis was performed using GraphPad
Prism Software Version 7.
Study approval. Animal experiments were conducted under the
ethical guidelines and protocols approved by IACUC at Yale University School of Medicine (Animal protocol no. 2019-116576). All human
tissues were collected with the approval from the Yale Human Investigation Committee (protocol no. 9505008219). The Yale Human
Investigation Committee approved the patient consent forms or in
some cases, a waiver of consent.
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